Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development stage life sciences company developing a single-molecule proteome analysis platform, and the news surrounding NAUT often centers on progress toward validating and deploying this technology. The company’s communications highlight its Iterative Mapping method, tau proteoforms assay, and collaborations with leading research institutions as key themes in its news flow.
Readers following Nautilus news can expect updates on platform development milestones, such as the successful installation and testing of the first external field evaluation unit at the Buck Institute for Research on Aging. News has described how researchers at the Buck Institute generated highly reproducible tau proteoform data from neurodegenerative disease samples and used the Nautilus Proteome Analysis Platform to explore region-specific proteoform patterns associated with disease progression.
NAUT news also covers agreements and collaborations, including an agreement with the Allen Institute focused on investigating the connection between tau protein and neurodegenerative conditions such as Alzheimer’s disease. These announcements often discuss efforts to identify novel tau proteoforms, quantify their prevalence, and characterize phosphorylation patterns that may help explain disease course.
Financial results and corporate updates are another important category of Nautilus news. The company regularly issues quarterly earnings press releases describing operating expenses, net loss, cash, cash equivalents, and investments, along with commentary on development progress and plans for its platform and Early Access Program. Investors can also find notices about upcoming earnings calls, participation in healthcare and investor conferences, and regulatory filings reported via Form 8-K.
In addition, Nautilus has announced an Early Access Program for its proteomics platform, starting with a tau proteoforms assay, which is a recurring topic in its news. These articles explain how selected researchers gain access to the Iterative Mapping method, receive support for data interpretation and analysis, and participate in custom assay development partnerships. For anyone tracking NAUT, this news page provides a centralized view of technology, collaboration, commercialization, and financial developments related to the company’s single-molecule proteomics efforts.
Nautilus (NASDAQ: NAUT) appointed Amber Faust as Vice President of Sales to lead commercialization of the Nautilus Voyager™ Platform.
The hire follows the public debut of Voyager and launch of the Iterative Mapping Early Access Program; Nautilus plans to initiate commercial launch of Voyager in late 2026.
The company’s first assay, Tau Proteoforms, is already in active use at the Buck Institute.
Nautilus Biotechnology (NASDAQ: NAUT) reported Q4 and fiscal 2025 results on Feb 26, 2026. Operating expenses fell to $15.4M in Q4 and $66.8M for FY2025, while net loss was $13.8M in Q4 and $59.0M for FY2025. Cash and investments totaled $156.1M as of Dec 31, 2025.
The company launched an Iterative Mapping Early Access Program in Jan 2026, advanced platform validation with Tau proteoform data, and initiated a Michael J. Fox Foundation–supported collaboration for alpha-synuclein assays. Nautilus expects no material Early Access revenue in 2026 and forecasts operating expense growth of 15–20% year over year, believing cash suffices to fund operations through 2027.
Nautilus Biotechnology (NASDAQ: NAUT) unveiled the Voyager™ Platform at US HUPO 2026, a benchtop system designed to enable Iterative Mapping of up to 10 billion intact proteins and proteoforms in a single run. The company began an Early Access Program in Jan 2026 and expects commercial launch in late 2026.
Field evaluation at the Buck Institute produced reproducible tau proteoform insights; initial offerings include a Tau Proteoforms assay quantifying up to 768 full-length tau proteoform groups. Limited instrument placements will precede broad commercial availability.
Nautilus Biotechnology (NASDAQ: NAUT) will participate in the TD Cowen 46th Annual Health Care Conference. Management is scheduled for a fireside chat on March 2, 2026 at 10:30 a.m. ET. A live and archived webcast will be available on the company Investors website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) will report fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026. Management will host a webcast and conference call to discuss results, business developments, and outlook.
Live audio will be available on the company’s Investors webpage at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) announced a research collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation supported by a $1.6 million MJFF grant to develop a single-molecule assay measuring alpha-synuclein proteoforms for Parkinson’s disease biomarker research.
The project pairs Nautilus’ Iterative Mapping single-molecule proteomics platform with Lashuel lab expertise to probe post-translational modifications and enable improved disease detection, stratification, and monitoring.
Nautilus Biotechnology (NASDAQ: NAUT) launched an Early Access Program on Jan 8, 2026 to provide select researchers with initial access to its single-molecule proteomics platform using the company's Iterative Mapping method, beginning with a validated tau proteoforms assay.
The program offers exclusive use for an initial group, support for data interpretation and custom assay development, and aims to accelerate Alzheimer’s and neurodegenerative research. A Nautilus preprint and early external deployment at the Buck Institute reported mapping of up to 768 distinct tau proteoforms across brain regions, and the company will host a webinar on Jan 14, 2026 to present updated collaboration data.
Nautilus (NASDAQ: NAUT) installed and tested its first external field evaluation unit at the Buck Institute, running the instrument for more than 6 months on neurodegenerative disease samples and producing highly reproducible end-to-end data across sites and users.
The unit uses Nautilus’ Iterative Mapping approach and a proprietary tau proteoform assay that quantifies 768 proteoform groups. Results will be presented at the HUPO World Congress on Nov 10, 2025, and may support future joint publications.
Nautilus Biotechnology (NASDAQ: NAUT) reported third quarter 2025 results for the period ended September 30, 2025. Key operational milestones include continued processing of Tau proteoform samples with collaborators and progress on a broadscale assay format intended to support a commercial launch in late 2026. The company expects an early access program for Tau proteoforms in the first half of 2026 and plans to share collaborator data at the upcoming World HUPO conference.
Financial highlights: Operating expenses were $15.5 million in Q3 2025, down 19% year-over-year; net loss was $13.6 million versus $16.4 million a year earlier; and cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025. A conference call and webcast were scheduled for October 28, 2025 at 5:30 AM PT.
Nautilus Biotechnology (NASDAQ: NAUT) will report third quarter 2025 financial results before market open on Tuesday, October 28, 2025. Management will host a webcast and conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Live audio will be available on the company’s Investors website at www.nautilus.bio. Investors can listen to the webcast for prepared remarks and management Q&A covering the quarter’s performance and near‑term plans.